About US
Contact us
-
UPDATED: FDA asks Pfizer for Zoloft label update highlighting birth defect risksFor years, Pfizer ($PFE) has shrugged off claims that its antidepressantZoloftcauses heart defects in newborns, fighting a raft of litigation alleging that the company did not adequately warn pregnant2015/9/21
-
Celgene's Abraxane takes another hit from cost-effectiveness gatekeepersCelgene's ($CELG)Abraxanecan't catch a break in England. Soon after losing coverage for pancreatic cancer on the country's dedicatedCancer Drugs Fund, the treatment got another thumbs-down from its of2015/9/18
-
Lilly, BI's Jardiance posts 'amazing' 14% reduction in major CV eventsSince Eli Lilly ($LLY) andBoehringer Ingelheimannounced that theirSGLT2med,Jardiance, had become the first to show it could lower the risk of major cardiovascular events, the question on the minds of2015/9/18
-
Victoza tops Sanofi's Lyxumia in trial, adding to Novo's GLP-1 arsenalCompetition is heating up in the GLP-1 diabetes market, and Novo Nordisk ($NVO) is doing what it can to line up data behind its long-dominant drug,Victoza. The latest: A study pitting the brand agains2015/9/17
-
BMS' Opdivo guns for kidney cancer nod with FDA 'breakthrough' tagLast July, Bristol-Myers Squibb ($BMY) put an early end to a late-stage study that showed its immunotherapy drug,Opdivo, looked good in patients with advancedkidney cancer. And now, it's one step clos2015/9/17
-
Novartis priced Entresto on par with results, new cost watchdog saysA new U.S. cost-effectiveness watchdog has now weighed in on three of the most hotly anticipated drug launches of 2015. And so far, pharma has scored just one out of three. Last week, the Institute f2015/9/16
-
Novo racks up Tresiba data for impending mano a mano with Sanofi's ToujeoNovo Nordisk is out trumpeting new data on its next-gen basal insulinTresibaand a combo med, Xultophy. New studies to brag about are always good things. But they're particularly well-timed now, with t2015/9/16
-
J&J does a quick about-face on $1B media account moveApparently you can go home again. Just a year after switching U.S. media buying partners, Johnson & Johnson ($JNJ) is taking its $1 billion media account back to J3, a J&J-dedicated unit insid2015/9/15
-
Takeda gets enough takers to complete $2.3B Actos settlementA month ago it appeared likeTakedamight not get enough takers to move forward with its sweeping $2.3 billion offer to settle thousands of claims over the cancer risks of diabetes drugActos. But over t2015/9/15
-
Why is Novartis' Copaxone copy lagging? It's all about coverage, analyst explainsTypically, the first generics for blockbuster meds get off to a running start. Not so with Novartis' ($NVS) generic of Teva's ($TEVA) multiple sclerosis standoutCopaxone, though--and Bernstein analyst2015/9/14